Terlipressin therapy for renal failure in cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 4, 2010, Pages 481-486

  Triantos, Christos K ^a,b   Samonakis, Dimitrios ^a   Thalheimer, Ulrich ^a   Cholongitas, Evangelos ^a   Senzolo, Marco ^a   Marelli, Laura ^a   Leandro, Gioacchino ^a   Patch, David ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Cirrhosis; Hepatorenal syndrome; Terlipressin

Indexed keywords

ALBUMIN; CREATININE; TERLIPRESSIN;

ADULT; AGED; ANURIA; ARTICLE; COMORBIDITY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE ISCHEMIA; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OLIGURIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CREATININE; ELECTROLYTES; FEMALE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMANS; KIDNEY FAILURE; LIVER CIRRHOSIS; LYPRESSIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TREATMENT OUTCOME; UREA; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 77949456635     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283345524     Document Type: Article

References (32)

1. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32 (1 Suppl):157-170.
2. Davis CL, Gonwa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002; 8:91-109.
3. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37:233-243.
4. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48:2064-2077.
5. Moreau R, Lebrec D. Review article: hepatorenal syndrome-definitions and diagnosis. Aliment Pharmacol Ther 2004; 20 (Suppl 3):24-28.
6. Salerno F, Gerbes A, Gines P,Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310-1318.
7. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362:1819-1827.
8. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229-236.
9. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006; 26:834-839.
10. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43:385-394.
11. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:43-48.
12. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14:1363-1368.
13. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40:140-146.
14. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006; 4:CD005162.
15. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24:935-944.
16. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360-1368.
17. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134:1352-1359.
18. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874.
19. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334:1448-1460.
20. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology 2007; 45:223-229.
21. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17:882-888.
22. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14:153-158.
23. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36 (4 Pt 1):941-948.
24. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103:1689-1697.
25. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64:15-19.
26. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122:923-930.
27. Duhamel C, Mauillon J, Berkelmans I, Bourienne A, Tranvouez JL. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 2000; 95:2984-2985.
28. Gow PJ, Testro AG, Angus PW. Terlipressin therapy for hepatorenal syndrome-which patients should be treated? (Abstract). Hepatology 2004; 40 (4 Suppl 1):643A.
29. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial. J Gastroenterol Hepatol 2003; 18:152-156.
30. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41:1282-1289.
31. Terra C, Guevara M,Torre A, Gilabert R, Fernandez J, Martin-Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129:1944-1953.
32. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164-176.